ACL
ABVX

APEIRON Capital Ltd’s Abivax ABVX Stock Holding History

APEIRON Capital Ltd’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Buy
+130,600
New +$14.8M 11.18% 3

Other funds holding ABVX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

APEIRON Capital Ltd's ABVX Position: Q2 2026 in Review

APEIRON Capital Ltd opened a new position in Abivax (ABVX) in Q2 2026: 130,600 shares worth $17.4M. The stake represents 11.18% of the portfolio and ranks #3 among its holdings.

86 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • APEIRON Capital Ltd held 130,600 shares of Abivax worth $17.4M as of Q2 2026.
  • Abivax was a new APEIRON Capital Ltd position in Q2 2026.
  • Abivax made up 11.18% of APEIRON Capital Ltd's portfolio in Q2 2026, its #3 holding.
  • 86 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on APEIRON Capital Ltd's 13F filing for Q2 2026, filed 6 Aug 2026.